	US 12,319,732 B2
	Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same
Ji Chul Lee, Gyeonggi-do (KR); Jongchan Park, Gyeonggi-do (KR); Sung-Won Min, Seoul (KR); and Hyeong Sun Kwon, Seoul (KR)
Assigned to SG MEDICAL INC., Seoul (KR)
Appl. No. 17/422,265
Filed by SG MEDICAL INC., Seoul (KR)
PCT Filed Jan. 8, 2020, PCT No. PCT/KR2020/000353 § 371(c)(1), (2) Date Jul. 12, 2021, PCT Pub. No. WO2020/145669, PCT Pub. Date Jul. 16, 2020.
Claims priority of application No. 10-2019-0003213 (KR), filed on Jan. 10, 2019; and application No. 10-2020-0002048 (KR), filed on Jan. 7, 2020.
Prior Publication US 2022/0372132 A1, Nov. 24, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 39/00 (2013.01); A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); G01N 33/574 (2013.01)]

14 Claims

1. A monoclonal antibody or fragment thereof that recognizes and binds specifically to beta 1 integrin as an antigen wherein the monoclonal antibody or fragment thereof comprises replaced amino acids at the following positions according to the Kabat EU numbering system:

a) the heavy chain variable region (VH) SEQ ID NO: 1 with substitutions A9S, 120V, T25S, S30T, K67R, S76T, N77D, and Q82E; and

b) the light chain variable region (VL) SEQ ID NO: 2 with substitutions V11L, F41Y, and R44K.